Vectura Group plc Release: AirFluSal Forspiro Launched In Portugal And Ireland
•50-250 µg and 50-500 µg dosage forms launched in Portugal and Ireland
• Innovative inhaler offers asthma and COPD patients a new therapeutic option
• Now available to patients in 14 countries as the global roll-out continues apace
Chippenham, UK – 11th March 2015: Vectura Group plc (LSE: VEC; “Vectura” or “the Company”) confirms that our partner Sandoz, has announced the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.
AirFluSal® Forspiro®, which was first approved in Denmark, has now been launched in a total of a dozen European countries, as well as South Korea and Mexico. It has been approved in more than two dozen countries and our partner confirms that the planned global roll-out continues apace on a market-by-market basis, in line with local regulatory requirements.
AirFluSal® Forspiro® offers the proven combination of salmeterol (a long-acting inhaled ß2-agonist) and fluticasone propionate (an inhaled corticosteroid) in an innovative new device. The product’s safety, efficacy and equivalence have been proven in multiple clinical trials.
Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal® Forspiro® by Aeropharm GmbH in Rudolstadt, Germany, Sandoz’s global respiratory Center of Excellence. The innovative and intuitive-to-use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognised quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.
-Ends-
Enquiries
Vectura Group plc +44 (0)1249 667700
Chris Blackwell, Chief Executive
Andrew Oakley, Chief Financial Officer
Karl Keegan, Chief Corporate Development Officer
FTI Consulting +44 (0)20 3727 1000
Ben Atwell / John Dineen / Ulla Lundhus
About Vectura
Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $46 billion worldwide.
Vectura now has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura currently has disclosed development collaborations and license agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company.
Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.
For further information, please visit Vectura's website at www.vectura.com.
Help employers find you! Check out all the jobs and post your resume.
• Innovative inhaler offers asthma and COPD patients a new therapeutic option
• Now available to patients in 14 countries as the global roll-out continues apace
Chippenham, UK – 11th March 2015: Vectura Group plc (LSE: VEC; “Vectura” or “the Company”) confirms that our partner Sandoz, has announced the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.
AirFluSal® Forspiro®, which was first approved in Denmark, has now been launched in a total of a dozen European countries, as well as South Korea and Mexico. It has been approved in more than two dozen countries and our partner confirms that the planned global roll-out continues apace on a market-by-market basis, in line with local regulatory requirements.
AirFluSal® Forspiro® offers the proven combination of salmeterol (a long-acting inhaled ß2-agonist) and fluticasone propionate (an inhaled corticosteroid) in an innovative new device. The product’s safety, efficacy and equivalence have been proven in multiple clinical trials.
Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal® Forspiro® by Aeropharm GmbH in Rudolstadt, Germany, Sandoz’s global respiratory Center of Excellence. The innovative and intuitive-to-use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognised quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.
-Ends-
Enquiries
Vectura Group plc +44 (0)1249 667700
Chris Blackwell, Chief Executive
Andrew Oakley, Chief Financial Officer
Karl Keegan, Chief Corporate Development Officer
FTI Consulting +44 (0)20 3727 1000
Ben Atwell / John Dineen / Ulla Lundhus
About Vectura
Vectura is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $46 billion worldwide.
Vectura now has eight products marketed by partners with growing global royalty streams and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura currently has disclosed development collaborations and license agreements with several global pharmaceutical and biotechnology companies, including Novartis, Sandoz, Baxter, GlaxoSmithKline, UCB, Ablynx, Grifols, Janssen Biotech and Tianjin KingYork Group Company.
Vectura develops products for airways diseases and owns formulation and inhalation technologies that are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.
For further information, please visit Vectura's website at www.vectura.com.
Help employers find you! Check out all the jobs and post your resume.